The 11th Abu Dhabi International Conference in Dermatology and Aesthetics is going to be from May 2nd–4th, 2025
Abu Dhabi, Building on the remarkable success of the previous editions, the 11th Abu Dhabi International Conference in Dermatology and Aesthetics (AIDA), will be held during May 2-4, 2025, at the prestigious Conrad Hotel in Etihad Towers, Abu Dhabi, UAE. The 4th of May will be conducted virtually in order to facilitate greater accessibility for participants on a global scale.
AIDA will play host to a significant number of international experts, specialists, doctors, and lecturers. The event will feature approximately 60 experts and specialists from the UAE and other countries, who will present their experiences and expertise in the treatment of skin diseases, cosmetic surgery, laser therapy, and the utilisation of artificial intelligence and the industrial revolution to deliver optimal treatment methods.
The Department of Culture and Tourism - Abu Dhabi is supporting and sponsoring this prestigious event, which is being attended by leading specialists in dermatology, cosmetics and laser treatments from the GCC countries, the Middle East and internationally renowned institutions.
The conference will address recent advancements in the domains of dermatology, aesthetics, anti-aging medicine, lasers, and cosmetics. Furthermore, it will facilitate the identification of novel and sophisticated treatments for various skin-related conditions, the implementation of optimal evidence-based strategies and practices, the integration of acquired knowledge into patient care and treatment, and the utilisation of available treatment options that contribute to the development of clinical practices and the enhancement of healthcare quality.
Dr. Khaled Othman, Consultant Dermatology-Founder and Conference President, said that the UAE's healthcare sector is receiving tremendous support from its prudent leadership. Their commitment to providing the best healthcare possible to their citizens and residents is truly commendable. The leadership has established an advanced healthcare infrastructure and prepared distinguished human cadres to provide treatment at the highest levels, making the country a leading destination for hosting international medical conferences.
'This edition of AIDA has attracted a select group of specialists from around the world. They came to share inspiration, knowledge and pioneering ideas that shape dermatology and aesthetics in the UAE, the Middle East and the world,' Dr. Othman added.
He also noted that the conference's specialised scientific committee has prepared a comprehensive programme covering everything related to dermatology and aesthetic surgery, dermatology, anti-aging techniques, laser technology, and other dermatological specialties.
Dr. Khaled Othman is certain that this year's conference will provide a valuable platform for networking and building professional relationships. It aspires to drive innovation in dermatology and aesthetic medicine, contributing to improved patient care and higher standards of treatment.
Dr. Meera Al Adawi, Conference Vice President, Dermatology Consultant at Sheikh Khalifa Medical City (SKMC), stated that a distinguished programme has been meticulously prepared for the conference. This programme includes the organisation of workshops and competitions for resident physicians from the UAE and the GCC countries with a view to qualifying the participants, refining their skills, and augmenting their experience in their respective fields of specialisation in dermatology and cosmetic medicine.
She also said that the conference's supervisory committees have meticulously crafted a diverse array of immersive and interactive activities, with the objective of enhancing the conference experience for all participants. These activities encompass a wide range of formats, including practical workshops, expert meeting sessions, keynote presentations, case studies, live demonstrations, and research summaries on dermatology and aesthetics.
For her part, Dr. Fatima Hasan Al Marzooqi, Scientific Committee Chair, Consultant Dermatologist, and Head of Dermatology Department at Zayed Military Hospital, said that all dermatological medical associations from the UAE, the GCC countries, and the Arab countries have been invited to participate in the conference. These associations have been invited to speak during its sessions, deliver specialised lectures, and discuss important research papers.
Dr. Huda Rajab Ali, Scientific Committee Co-Chair, Chair of Dermatology Department, AHS-SEHA, Abu Dhabi, UAE has asserted that Abu Dhabi holds significant importance as a venue for specialized medical conferences. These conferences serve as pivotal platforms, offering medical and technical personnel invaluable expertise and experience through the discourse and research presented.
The AIDA-2025 will be the place to see the latest developments in the diagnosis and treatment of dermatological diseases, laser therapy techniques and aesthetic treatment. Moreover, this year's edition will feature 25 exhibitors showcasing the latest devices and medical equipment related to dermatology, cosmetic and laser medicine.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
10 hours ago
- Khaleej Times
'We sleep much better': Why Zayed Sustainability Prize winner lit up remote Africa
Spending the first five years of her life in the turmoil of Lebanon's civil war in the early 1980s, Angela Homsi remembers a world without electricity and basic luxuries. That memory shaped her mission to bring clean, sustainable energy to underserved communities, especially in Africa. Now, over four decades later, Homsi is leading Ignite Power, a renewable energy company she co-founded, from a new global headquarters in Abu Dhabi. 'We cannot be more excited by this latest development,' Homsi, winner of the 2024 Zayed Sustainability Prize in the Energy category, told Khaleej Times. 'There's no nation out there in the world more aligned with what we want to do and achieve with our impacts than the UAE.' Ignite Power provides solar-powered electricity and internet to some of Africa's most remote communities. The company currently operates in 15 countries and is aiming to reach 100 million people over the next five years. 'We're on a very high growth path, and the UAE is really at the centre of 2.5 to 3 billion people. It's a very strategic location for logistics, economic power, and influence.' Lighting up lives The impact of Ignite's work is far-reaching. In rural Rwanda, the arrival of solar home systems has transformed daily life for families. 'Now, with the lights, we sleep much better,' said Mukande Qwe, a mother of three in Gisagara. 'We used to sleep with the cows before because it wasn't safe to leave them outside due to the many thefts after dark. Now, thanks to the light, we keep them outside, and everybody has more room to sleep comfortably.' Beneficiaries across the country echoed similar stories of transformation. Nakabonye Daforosa, a 70-year-old resident of Rulindo, said: 'My granddaughter is able to do her homework after dark and is getting higher grades. The radio helps me stay updated… the solar torch allows me to walk outside after dark.' Odetta Musabyimana, 58, lives alone in Gisagara. 'I feel much safer with the lights on… I also save 100 francs a month since I don't have to buy petrol anymore. I have time to make mattresses, giving them to neighbours and friends who cannot afford to buy one.' Other households have seen a boost in agricultural output and income. 'Before we had light, we sold 20kg of beans and 30kg of maize, and now we are selling 40kg of beans and 60kg of maize,' said Tasiana Irikunze, a mother of two from Kabunjwiri village. 'When we didn't have light, we lost crops due to rotting. Now we have more time to process them.' Solar-powered irrigation has also made a difference. 'We used to sell 200kg, and now it is 500kg,' said Mukamparaye Jeanne from Kivomo. 'Before, we used a generator and petrol to fuel it, 5L per day… extremely expensive and not even half as beneficial.' For Nsabimana Deogen, a farmer and mother in Rulindo, the benefits are personal and financial. 'With proper light, I can cook clean food, and my family's health has gotten much better for it. The light has given my children time to study and do their homework, their grades are rising, and they have much higher motivation to succeed.' Homsi, now 44, was born in Lebanon in 1980 and moved to Cairo at age five. She later lived in Europe and pursued a career in investment, working with Goldman Sachs and Generation Investment Management, the sustainability fund chaired by former US Vice President Al Gore. 'I always wanted to make an impact on the wider continent,' she said. 'To do something that will change the direction of Africa and the Middle East.' Ignite began not as a company, but as a white paper. 'Most countries in Africa only had around 20 per cent of their population with access to electricity,' Homsi explained. 'Eighty percent were using kerosene lamps, damaging to health, education, and economic development.' The first project was launched in Rwanda after Homsi and her team presented a vision to the country's president. 'We supported writing a proper socio-economic feasibility study on how Rwanda could become the first fully connected country in Africa.' Growth through Abu Dhabi Since receiving the Zayed Sustainability Prize, Homsi said Ignite has grown eightfold. 'That's huge. Above and beyond our own expectation,' she said. The award helped raise visibility and credibility. 'We've always had our head on the ground, making sure every single dollar goes to the deepest possible impact." "The prize helped us tell our story.' One of the company's most promising initiatives is the solar-plus-internet deployment in schools. 'We deployed the first 30 schools right after the prize,' she said. 'That pilot is now shaping the way for the next 10,000 schools in multiple countries.' Homsi believes Abu Dhabi offers the infrastructure and values to support the firm's ambitious growth. 'We've already incorporated in the UAE, finalised office spaces, and started hiring. The office will host our senior management, R&D, business development, procurement, and public affairs roles — functions that cover multi-country operations.' She also plans to deepen ties with UAE universities. 'I dedicate a large amount of my time to education, advocacy, teaching… we need more youth to be inspired, to take over the flame, and carry on the mission.' For Homsi, impact and scale go hand in hand. 'You cannot scale the amount of people you will impact… if you cannot scale your business. It has to be a strong business that attracts top talent and achieves deep, lasting change,' she concluded.
Zawya
13 hours ago
- Zawya
M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care
Partnership will advance cancer diagnosis, inform treatment decisions, and enable real-time monitoring of disease progression in a more cost-effective and less invasive manner The launch is expected in the latter part of Q2 2025, following the completion of an initial validation study at Cleveland Clinic Abu Dhabi Abu Dhabi, United Arab Emirates: M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionize health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS (Nasdaq: SOPH) to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing program will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Over time, the collaboration will serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia, delivering world-class precision oncology solutions to a wider population. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said: "At M42, we are committed to transforming care through innovation and collaboration. By partnering with AstraZeneca and SOPHiA GENETICS, we are bringing world-class liquid biopsy technologies to the UAE, empowering clinicians to deliver more precise and less invasive cancer care. This collaboration reflects our vision of democratizing health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care." Sameh El Fangary, Cluster President GCC, AstraZeneca, shared," At AstraZeneca, we are leading the way in the application of precision medicine. Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimizing patient pathways from detection to therapy.' R oss Muken, President of SOPHiA GENETICS, said: "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalize care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." About M42 M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
Zawya
15 hours ago
- Zawya
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care.' Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region."
